A greater number of mast cells are present in the conjunctiva of glaucoma patients who have undergone ocular surgery, possibly leading to increased scarring, according to study results published online ahead of print by Eye.
A greater number of mast cells are present in the conjunctiva of glaucoma patients who have undergone ocular surgery, possibly leading to increased scarring, according to study results published online ahead of print by Eye.
Lydia Chang of the Paediatric Glaucoma Service at Moorfields Eye Hospital, London, UK and colleagues identified the presence of tryptase, the intracellular mast cell enzyme, in the conjunctiva of glaucoma patients treated medically (n=6), with repeated surgery (n=8) and for uveitic glaucoma (n=7). They compared the tryptase levels with those found in the conjunctival biopsies of the control group (retinal detachment patients, n=8).
The median tryptase level of the control group was 0.064 cells/mm2; among the glaucoma groups, the median level ranged from 0.102 cells/mm2 to 0.113 cells/mm2. There was a statistically significant difference between the tryptase level of the surgery glaucoma group when compared with control, although this statistically significant difference did not exist between the control group and either of the other glaucoma groups.
Because the tryptase levels were higher in glaucoma patients who had previously undergone surgery, the researchers concluded that the activity of mast cells may contribute to post-trabeculectomy conjunctival scarring.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.